APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide and Oligonucleotide Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Peptide and Oligonucleotide Drugs Industry Growth and Trends Forecast to 2032

28 December 2025117 pages

Choose your research edition.

Industry ResearchPeptide and Oligonucleotide Drugs Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide and Oligonucleotide Drugs Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Peptide and Oligonucleotide Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide and Oligonucleotide Drugs Market Outlook and Growth Opportunities 2026202 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide and Oligonucleotide Drugs Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Peptide and Oligonucleotide Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide and Oligonucleotide Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Peptide and Oligonucleotide Drugs include Takeda, Sanofi, Novartis, Roche, Lilly, SciClone Pharmaceuticals, Sarepta Therapeutics, Nippon Shinyaku and Moderna, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Peptide and Oligonucleotide Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Peptide and Oligonucleotide Drugs market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Peptide and Oligonucleotide Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Peptide and Oligonucleotide Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Peptide and Oligonucleotide Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Peptide and Oligonucleotide Drugs Market by Company

Takeda

Sanofi

Novartis

Roche

Lilly

SciClone Pharmaceuticals

Sarepta Therapeutics

Nippon Shinyaku

Moderna

MiNA Therapeutics

Merck Serono

Ipsen PHarma Biotech

Ionis

Ferring Pharmaceuticals

BioNTech

AstraZeneca

Asahi Kasei

Alnylam

Peptide and Oligonucleotide Drugs Segment by Type

Oligonucleotide Drugs

Peptide Drugs

Peptide and Oligonucleotide Drugs Segment by Application

Oncology Drugs

Digestive system Drugs

Immunomodulatory Drugs

Bone and Connective Tissue Types

Other

Peptide and Oligonucleotide Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide and Oligonucleotide Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide and Oligonucleotide Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide and Oligonucleotide Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Peptide and Oligonucleotide Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Peptide and Oligonucleotide Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Oligonucleotide Drugs Table 2. Major Company of Peptide Drugs Table 3. Global Peptide and Oligonucleotide Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 5. Global Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global Peptide and Oligonucleotide Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global Peptide and Oligonucleotide Drugs Price by Type (2021-2026) & (US$/Unit) Table 9. Global Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (K Units) Table 10. Global Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global Peptide and Oligonucleotide Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global Peptide and Oligonucleotide Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global Peptide and Oligonucleotide Drugs Price by Type (2027-2032) & (US$/Unit) Table 14. North America Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 15. North America Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 17. Europe Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 19. Asia-Pacific Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 21. Latin America Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (K Units) Table 23. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Peptide and Oligonucleotide Drugs Industry Trends Table 25. Peptide and Oligonucleotide Drugs Industry Drivers Table 26. Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges Table 27. Peptide and Oligonucleotide Drugs Industry Restraints Table 28. Global Peptide and Oligonucleotide Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Peptide and Oligonucleotide Drugs Revenue Market Share by Company (2021-2026) Table 30. Global Peptide and Oligonucleotide Drugs Sales by Company (2021-2026) & (K Units) Table 31. Global Peptide and Oligonucleotide Drugs Sales Share by Company (2021-2026) Table 32. Global Peptide and Oligonucleotide Drugs Market Price by Company (2021-2026) & (US$/Unit) Table 33. Global Peptide and Oligonucleotide Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Peptide and Oligonucleotide Drugs Major Company Production Sites and Headquarters Table 35. Global Peptide and Oligonucleotide Drugs Company, Product Type & Application Table 36. Global Peptide and Oligonucleotide Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Peptide and Oligonucleotide Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Peptide and Oligonucleotide Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2026) & (K Units) Table 41. Global Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global Peptide and Oligonucleotide Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global Peptide and Oligonucleotide Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 45. Global Peptide and Oligonucleotide Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global Peptide and Oligonucleotide Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global Peptide and Oligonucleotide Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global Peptide and Oligonucleotide Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 50. Global Peptide and Oligonucleotide Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 52. Global Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global Peptide and Oligonucleotide Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global Peptide and Oligonucleotide Drugs Price by Application (2021-2026) & (US$/Unit) Table 56. Global Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (K Units) Table 57. Global Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global Peptide and Oligonucleotide Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global Peptide and Oligonucleotide Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global Peptide and Oligonucleotide Drugs Price by Application (2027-2032) & (US$/Unit) Table 61. North America Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 62. North America Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 64. Europe Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 66. Asia-Pacific Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 68. Latin America Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (K Units) Table 70. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Takeda Company Information Table 72. Takeda Business Overview Table 73. Takeda Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Takeda Peptide and Oligonucleotide Drugs Product Portfolio Table 75. Takeda Recent Development Table 76. Sanofi Company Information Table 77. Sanofi Business Overview Table 78. Sanofi Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Sanofi Peptide and Oligonucleotide Drugs Product Portfolio Table 80. Sanofi Recent Development Table 81. Novartis Company Information Table 82. Novartis Business Overview Table 83. Novartis Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Novartis Peptide and Oligonucleotide Drugs Product Portfolio Table 85. Novartis Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Roche Peptide and Oligonucleotide Drugs Product Portfolio Table 90. Roche Recent Development Table 91. Lilly Company Information Table 92. Lilly Business Overview Table 93. Lilly Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Lilly Peptide and Oligonucleotide Drugs Product Portfolio Table 95. Lilly Recent Development Table 96. SciClone Pharmaceuticals Company Information Table 97. SciClone Pharmaceuticals Business Overview Table 98. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio Table 100. SciClone Pharmaceuticals Recent Development Table 101. Sarepta Therapeutics Company Information Table 102. Sarepta Therapeutics Business Overview Table 103. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio Table 105. Sarepta Therapeutics Recent Development Table 106. Nippon Shinyaku Company Information Table 107. Nippon Shinyaku Business Overview Table 108. Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio Table 110. Nippon Shinyaku Recent Development Table 111. Moderna Company Information Table 112. Moderna Business Overview Table 113. Moderna Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. Moderna Peptide and Oligonucleotide Drugs Product Portfolio Table 115. Moderna Recent Development Table 116. MiNA Therapeutics Company Information Table 117. MiNA Therapeutics Business Overview Table 118. MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio Table 120. MiNA Therapeutics Recent Development Table 121. Merck Serono Company Information Table 122. Merck Serono Business Overview Table 123. Merck Serono Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio Table 125. Merck Serono Recent Development Table 126. Ipsen PHarma Biotech Company Information Table 127. Ipsen PHarma Biotech Business Overview Table 128. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio Table 130. Ipsen PHarma Biotech Recent Development Table 131. Ionis Company Information Table 132. Ionis Business Overview Table 133. Ionis Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Ionis Peptide and Oligonucleotide Drugs Product Portfolio Table 135. Ionis Recent Development Table 136. Ferring Pharmaceuticals Company Information Table 137. Ferring Pharmaceuticals Business Overview Table 138. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio Table 140. Ferring Pharmaceuticals Recent Development Table 141. BioNTech Company Information Table 142. BioNTech Business Overview Table 143. BioNTech Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. BioNTech Peptide and Oligonucleotide Drugs Product Portfolio Table 145. BioNTech Recent Development Table 146. AstraZeneca Company Information Table 147. AstraZeneca Business Overview Table 148. AstraZeneca Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 149. AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio Table 150. AstraZeneca Recent Development Table 151. Asahi Kasei Company Information Table 152. Asahi Kasei Business Overview Table 153. Asahi Kasei Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 154. Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio Table 155. Asahi Kasei Recent Development Table 156. Alnylam Company Information Table 157. Alnylam Business Overview Table 158. Alnylam Peptide and Oligonucleotide Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 159. Alnylam Peptide and Oligonucleotide Drugs Product Portfolio Table 160. Alnylam Recent Development Table 161. North America Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 162. North America Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 163. North America Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2026) Table 164. North America Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 165. North America Peptide and Oligonucleotide Drugs Sales Market Share Forecast by Country (2027-2032) Table 166. North America Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. North America Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 168. North America Peptide and Oligonucleotide Drugs Market Share by Country (2021-2026) Table 169. North America Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. North America Peptide and Oligonucleotide Drugs Market Share Forecast by Country (2027-2032) Table 171. Europe Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 172. Europe Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 173. Europe Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2026) Table 174. Europe Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 175. Europe Peptide and Oligonucleotide Drugs Sales Market Share Forecast by Country (2027-2032) Table 176. Europe Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 177. Europe Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 178. Europe Peptide and Oligonucleotide Drugs Market Share by Country (2021-2026) Table 179. Europe Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 180. Europe Peptide and Oligonucleotide Drugs Market Share Forecast by Country (2027-2032) Table 181. Asia-Pacific Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 182. Asia-Pacific Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 183. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2026) Table 184. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 185. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Market Share Forecast by Country (2027-2032) Table 186. Asia-Pacific Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 187. Asia-Pacific Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 188. Asia-Pacific Peptide and Oligonucleotide Drugs Market Share by Country (2021-2026) Table 189. Asia-Pacific Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 190. Asia-Pacific Peptide and Oligonucleotide Drugs Market Share Forecast by Country (2027-2032) Table 191. Latin America Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 192. Latin America Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 193. Latin America Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2026) Table 194. Latin America Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 195. Latin America Peptide and Oligonucleotide Drugs Sales Market Share Forecast by Country (2027-2032) Table 196. Latin America Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 197. Latin America Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 198. Latin America Peptide and Oligonucleotide Drugs Market Share by Country (2021-2026) Table 199. Latin America Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 200. Latin America Peptide and Oligonucleotide Drugs Market Share Forecast by Country (2027-2032) Table 201. Middle East and Africa Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 202. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (2021-2026) & (K Units) Table 203. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Market Share by Country (2021-2026) Table 204. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032) & (K Units) Table 205. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Market Share Forecast by Country (2027-2032) Table 206. Middle East and Africa Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 207. Middle East and Africa Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026) & (US$ Million) Table 208. Middle East and Africa Peptide and Oligonucleotide Drugs Market Share by Country (2021-2026) Table 209. Middle East and Africa Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 210. Middle East and Africa Peptide and Oligonucleotide Drugs Market Share Forecast by Country (2027-2032) Table 211. Key Raw Materials Table 212. Raw Materials Key Suppliers Table 213. Peptide and Oligonucleotide Drugs Distributors List Table 214. Peptide and Oligonucleotide Drugs Customers List Table 215. Research Programs/Design for This Report Table 216. Authors List of This Report Table 217. Secondary Sources Table 218. Primary Sources List of Figures Figure 1. Peptide and Oligonucleotide Drugs Image Figure 2. Global Peptide and Oligonucleotide Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide and Oligonucleotide Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Peptide and Oligonucleotide Drugs Sales (2021-2032) & (K Units) Figure 5. Oligonucleotide Drugs Image Figure 6. Global Oligonucleotide Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 7. Peptide Drugs Image Figure 8. Global Peptide Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 9. Global Peptide and Oligonucleotide Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Peptide and Oligonucleotide Drugs Market Share by Type 2025 VS 2032 Figure 11. North America Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America Peptide and Oligonucleotide Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe Peptide and Oligonucleotide Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Peptide and Oligonucleotide Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Peptide and Oligonucleotide Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Oncology Drugs Image Figure 24. Global Oncology Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 25. Digestive system Drugs Image Figure 26. Global Digestive system Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 27. Immunomodulatory Drugs Image Figure 28. Global Immunomodulatory Drugs Sales YoY Growth (2021-2032) & (K Units) Figure 29. Bone and Connective Tissue Types Image Figure 30. Global Bone and Connective Tissue Types Sales YoY Growth (2021-2032) & (K Units) Figure 31. Other Image Figure 32. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 33. Global Peptide and Oligonucleotide Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Peptide and Oligonucleotide Drugs Market Share by Application 2025 VS 2032 Figure 35. North America Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Application in 2025 Figure 36. North America Peptide and Oligonucleotide Drugs Sales Market Share in Value by Application in 2025 Figure 37. Europe Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Europe Peptide and Oligonucleotide Drugs Sales Market Share in Value by Application in 2025 Figure 39. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Market Share in Value by Application in 2025 Figure 41. Latin America Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Latin America Peptide and Oligonucleotide Drugs Sales Market Share in Value by Application in 2025 Figure 43. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Market Share in Volume by Application in 2025 Figure 44. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Market Share in Value by Application in 2025 Figure 45. North America Peptide and Oligonucleotide Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 46. North America Peptide and Oligonucleotide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. North America Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. North America Peptide and Oligonucleotide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Peptide and Oligonucleotide Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 50. Europe Peptide and Oligonucleotide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Europe Peptide and Oligonucleotide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Peptide and Oligonucleotide Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 54. Asia-Pacific Peptide and Oligonucleotide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Asia-Pacific Peptide and Oligonucleotide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Peptide and Oligonucleotide Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 58. Latin America Peptide and Oligonucleotide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Latin America Peptide and Oligonucleotide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 62. Middle East and Africa Peptide and Oligonucleotide Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Peptide and Oligonucleotide Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Middle East and Africa Peptide and Oligonucleotide Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Peptide and Oligonucleotide Drugs Value Chain Figure 66. Key Raw Materials Price Figure 67. Manufacturing Cost Structure Figure 68. Peptide and Oligonucleotide Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Oligonucleotide Drugs
  • Peptide Drugs
Applications
  • Oncology Drugs
  • Digestive system Drugs
  • Immunomodulatory Drugs
  • Bone and Connective Tissue Types
  • Other
Companies covered
  • Takeda
  • Sanofi
  • Novartis
  • Roche
  • Lilly
  • SciClone Pharmaceuticals
  • Sarepta Therapeutics
  • Nippon Shinyaku
  • Moderna
  • MiNA Therapeutics
  • Merck Serono
  • Ipsen PHarma Biotech
  • Ionis
  • Ferring Pharmaceuticals
  • BioNTech
  • AstraZeneca
  • Asahi Kasei
  • Alnylam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide and Oligonucleotide Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Peptide and Oligonucleotide Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Peptide and Oligonucleotide Drugs Market by Type
  6. 1.3.1 Oligonucleotide Drugs
  7. 1.3.2 Peptide Drugs
  8. 1.4 Global Peptide and Oligonucleotide Drugs Market Size by Type
  9. 1.4.1 Global Peptide and Oligonucleotide Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Peptide and Oligonucleotide Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Peptide and Oligonucleotide Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Peptide and Oligonucleotide Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Peptide and Oligonucleotide Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Peptide and Oligonucleotide Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Peptide and Oligonucleotide Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Peptide and Oligonucleotide Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Peptide and Oligonucleotide Drugs Industry Trends
  2. 2.2 Peptide and Oligonucleotide Drugs Industry Drivers
  3. 2.3 Peptide and Oligonucleotide Drugs Industry Opportunities and Challenges
  4. 2.4 Peptide and Oligonucleotide Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Peptide and Oligonucleotide Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Peptide and Oligonucleotide Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Peptide and Oligonucleotide Drugs Price (2021-2026)
  4. 3.4 Global Peptide and Oligonucleotide Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Peptide and Oligonucleotide Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Peptide and Oligonucleotide Drugs Company, Product Type & Application
  7. 3.7 Global Peptide and Oligonucleotide Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Peptide and Oligonucleotide Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Peptide and Oligonucleotide Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Peptide and Oligonucleotide Drugs Tier 1, Tier 2, and Tier 3
4 Peptide and Oligonucleotide Drugs Regional Status and Outlook
  1. 4.1 Global Peptide and Oligonucleotide Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Peptide and Oligonucleotide Drugs Historic Market Size by Region
  3. 4.2.1 Global Peptide and Oligonucleotide Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Peptide and Oligonucleotide Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Peptide and Oligonucleotide Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Peptide and Oligonucleotide Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Peptide and Oligonucleotide Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Peptide and Oligonucleotide Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Peptide and Oligonucleotide Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Peptide and Oligonucleotide Drugs by Application
  1. 5.1 Peptide and Oligonucleotide Drugs Market by Application
  2. 5.1.1 Oncology Drugs
  3. 5.1.2 Digestive system Drugs
  4. 5.1.3 Immunomodulatory Drugs
  5. 5.1.4 Bone and Connective Tissue Types
  6. 5.1.5 Other
  7. 5.2 Global Peptide and Oligonucleotide Drugs Market Size by Application
  8. 5.2.1 Global Peptide and Oligonucleotide Drugs Market Size Overview by Application (2021-2032)
  9. 5.2.2 Global Peptide and Oligonucleotide Drugs Historic Market Size Review by Application (2021-2026)
  10. 5.2.3 Global Peptide and Oligonucleotide Drugs Forecasted Market Size by Application (2027-2032)
  11. 5.3 Key Regions Market Size by Application
  12. 5.3.1 North America Peptide and Oligonucleotide Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.2 Europe Peptide and Oligonucleotide Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.3 Asia-Pacific Peptide and Oligonucleotide Drugs Sales Breakdown by Application (2021-2026)
  15. 5.3.4 South America Peptide and Oligonucleotide Drugs Sales Breakdown by Application (2021-2026)
  16. 5.3.5 Middle East and Africa Peptide and Oligonucleotide Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Takeda
  2. 6.1.1 Takeda Company Information
  3. 6.1.2 Takeda Business Overview
  4. 6.1.3 Takeda Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Takeda Peptide and Oligonucleotide Drugs Product Portfolio
  6. 6.1.5 Takeda Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Peptide and Oligonucleotide Drugs Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Novartis Peptide and Oligonucleotide Drugs Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Roche
  20. 6.4.1 Roche Company Information
  21. 6.4.2 Roche Business Overview
  22. 6.4.3 Roche Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Roche Peptide and Oligonucleotide Drugs Product Portfolio
  24. 6.4.5 Roche Recent Developments
  25. 6.5 Lilly
  26. 6.5.1 Lilly Company Information
  27. 6.5.2 Lilly Business Overview
  28. 6.5.3 Lilly Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Lilly Peptide and Oligonucleotide Drugs Product Portfolio
  30. 6.5.5 Lilly Recent Developments
  31. 6.6 SciClone Pharmaceuticals
  32. 6.6.1 SciClone Pharmaceuticals Company Information
  33. 6.6.2 SciClone Pharmaceuticals Business Overview
  34. 6.6.3 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 SciClone Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
  36. 6.6.5 SciClone Pharmaceuticals Recent Developments
  37. 6.7 Sarepta Therapeutics
  38. 6.7.1 Sarepta Therapeutics Company Information
  39. 6.7.2 Sarepta Therapeutics Business Overview
  40. 6.7.3 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Sarepta Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
  42. 6.7.5 Sarepta Therapeutics Recent Developments
  43. 6.8 Nippon Shinyaku
  44. 6.8.1 Nippon Shinyaku Company Information
  45. 6.8.2 Nippon Shinyaku Business Overview
  46. 6.8.3 Nippon Shinyaku Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Nippon Shinyaku Peptide and Oligonucleotide Drugs Product Portfolio
  48. 6.8.5 Nippon Shinyaku Recent Developments
  49. 6.9 Moderna
  50. 6.9.1 Moderna Company Information
  51. 6.9.2 Moderna Business Overview
  52. 6.9.3 Moderna Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Moderna Peptide and Oligonucleotide Drugs Product Portfolio
  54. 6.9.5 Moderna Recent Developments
  55. 6.10 MiNA Therapeutics
  56. 6.10.1 MiNA Therapeutics Company Information
  57. 6.10.2 MiNA Therapeutics Business Overview
  58. 6.10.3 MiNA Therapeutics Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 MiNA Therapeutics Peptide and Oligonucleotide Drugs Product Portfolio
  60. 6.10.5 MiNA Therapeutics Recent Developments
  61. 6.11 Merck Serono
  62. 6.11.1 Merck Serono Company Information
  63. 6.11.2 Merck Serono Business Overview
  64. 6.11.3 Merck Serono Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Merck Serono Peptide and Oligonucleotide Drugs Product Portfolio
  66. 6.11.5 Merck Serono Recent Developments
  67. 6.12 Ipsen PHarma Biotech
  68. 6.12.1 Ipsen PHarma Biotech Company Information
  69. 6.12.2 Ipsen PHarma Biotech Business Overview
  70. 6.12.3 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Ipsen PHarma Biotech Peptide and Oligonucleotide Drugs Product Portfolio
  72. 6.12.5 Ipsen PHarma Biotech Recent Developments
  73. 6.13 Ionis
  74. 6.13.1 Ionis Company Information
  75. 6.13.2 Ionis Business Overview
  76. 6.13.3 Ionis Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Ionis Peptide and Oligonucleotide Drugs Product Portfolio
  78. 6.13.5 Ionis Recent Developments
  79. 6.14 Ferring Pharmaceuticals
  80. 6.14.1 Ferring Pharmaceuticals Company Information
  81. 6.14.2 Ferring Pharmaceuticals Business Overview
  82. 6.14.3 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 Ferring Pharmaceuticals Peptide and Oligonucleotide Drugs Product Portfolio
  84. 6.14.5 Ferring Pharmaceuticals Recent Developments
  85. 6.15 BioNTech
  86. 6.15.1 BioNTech Company Information
  87. 6.15.2 BioNTech Business Overview
  88. 6.15.3 BioNTech Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 BioNTech Peptide and Oligonucleotide Drugs Product Portfolio
  90. 6.15.5 BioNTech Recent Developments
  91. 6.16 AstraZeneca
  92. 6.16.1 AstraZeneca Company Information
  93. 6.16.2 AstraZeneca Business Overview
  94. 6.16.3 AstraZeneca Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 AstraZeneca Peptide and Oligonucleotide Drugs Product Portfolio
  96. 6.16.5 AstraZeneca Recent Developments
  97. 6.17 Asahi Kasei
  98. 6.17.1 Asahi Kasei Company Information
  99. 6.17.2 Asahi Kasei Business Overview
  100. 6.17.3 Asahi Kasei Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  101. 6.17.4 Asahi Kasei Peptide and Oligonucleotide Drugs Product Portfolio
  102. 6.17.5 Asahi Kasei Recent Developments
  103. 6.18 Alnylam
  104. 6.18.1 Alnylam Company Information
  105. 6.18.2 Alnylam Business Overview
  106. 6.18.3 Alnylam Peptide and Oligonucleotide Drugs Sales, Revenue and Gross Margin (2021-2026)
  107. 6.18.4 Alnylam Peptide and Oligonucleotide Drugs Product Portfolio
  108. 6.18.5 Alnylam Recent Developments
7 North America by Country
  1. 7.1 North America Peptide and Oligonucleotide Drugs Sales by Country
  2. 7.1.1 North America Peptide and Oligonucleotide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Peptide and Oligonucleotide Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Peptide and Oligonucleotide Drugs Market Size by Country
  6. 7.2.1 North America Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Peptide and Oligonucleotide Drugs Sales by Country
  2. 8.1.1 Europe Peptide and Oligonucleotide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Peptide and Oligonucleotide Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Peptide and Oligonucleotide Drugs Market Size by Country
  6. 8.2.1 Europe Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Peptide and Oligonucleotide Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Peptide and Oligonucleotide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Peptide and Oligonucleotide Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Peptide and Oligonucleotide Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Peptide and Oligonucleotide Drugs Sales by Country
  2. 10.1.1 South America Peptide and Oligonucleotide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Peptide and Oligonucleotide Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Peptide and Oligonucleotide Drugs Market Size by Country
  6. 10.2.1 South America Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Peptide and Oligonucleotide Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Peptide and Oligonucleotide Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Peptide and Oligonucleotide Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Peptide and Oligonucleotide Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Peptide and Oligonucleotide Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Peptide and Oligonucleotide Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Peptide and Oligonucleotide Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Peptide and Oligonucleotide Drugs Value Chain Analysis
  2. 12.1.1 Peptide and Oligonucleotide Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Peptide and Oligonucleotide Drugs Production Mode & Process
  7. 12.2 Peptide and Oligonucleotide Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Peptide and Oligonucleotide Drugs Distributors
  10. 12.2.3 Peptide and Oligonucleotide Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst